GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Tp53 | affects expression | EXP | | 6480464 | CTD | leptomycin B affects the expression of TP53 protein | PMID:11751435 | Tp53 | increases expression | EXP | | 6480464 | CTD | leptomycin B results in increased expression of TP53 protein | PMID:15459018 | Tp53 | multiple interactions | EXP | | 6480464 | CTD | alpha-naphthoflavone inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [leptomycin B results in increased expression of TP53 protein]]; Tetrachlorodibenzodioxin inhibits the reaction [leptomycin B results in increased expression of TP53 protein] | PMID:15459018 | Tp53 | decreases degradation | ISO | TP53 (Homo sapiens) | 6480464 | CTD | leptomycin B results in decreased degradation of TP53 protein | PMID:15625077 | Tp53 | increases expression | ISO | TP53 (Homo sapiens) | 6480464 | CTD | leptomycin B results in increased expression of TP53 protein | PMID:16467109 PMID:19751709 | Tp53 | increases response to substance | ISO | TP53 (Homo sapiens) | 6480464 | CTD | TP53 gene mutant form results in increased susceptibility to leptomycin B | PMID:20803015 | Tp53 | multiple interactions | ISO | TP53 (Homo sapiens) | 6480464 | CTD | 3,4,5,3',4'-pentachlorobiphenyl inhibits the reaction [leptomycin B results in increased expression of TP53 protein]; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of BRCA1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of CHEK2 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of DNMT1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of HK2 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of MDM4 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of PRKCA mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in decreased expression of TP63 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of APAF1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of BIRC5 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of IL6 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of NFKB1 mRNA; [leptomycin B co-treated with TP53 gene mutant form] results in increased expression of TNFRSF10D mRNA; [sodium arsenite co-treated with leptomycin B] results in increased phosphorylation of TP53 protein; leptomycin B affects the localization of and results in decreased degradation of TP53 protein; leptomycin B inhibits the reaction [Cycloheximide results in increased degradation of TP53 protein]; leptomycin B inhibits the reaction [sodium arsenite affects the localization of TP53 protein]; leptomycin B inhibits the reaction [sodium arsenite results in increased degradation of TP53 protein mutant form]; leptomycin B inhibits the reaction [TP53 protein results in increased susceptibility to trichostatin A]; PCB 180 promotes the reaction [leptomycin B results in increased expression of TP53 protein]; Pravastatin inhibits the reaction [leptomycin B results in decreased degradation of TP53 protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in decreased expression of BIRC5 protein]; TP53 gene mutant form inhibits the reaction [leptomycin B results in increased expression of CDKN1A protein] | PMID:15625077 PMID:16467109 PMID:19010883 PMID:19751709 PMID:20803015 PMID:21454520 PMID:24792400 PMID:31645432 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |